Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Fibrogenesis and inflammation contribute to the pathogenesis of cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Validation of suPAR turbidimetric assay on Cobas® (c502 and c702) and comparison to suPAR ELISA

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Elevated suPAR Is an Independent Risk Marker for Incident Kidney Disease in Acute Medical Patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Post-hospital medical respite care for homeless people in Denmark: a randomized controlled trial and cost-utility analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
ABSTRACT: INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is the soluble form of the membrane-bound receptor (uPAR) expressed predominantly on various immune cells. Elevated plasma suPAR concentration is associated with increased mortality in various patient groups, and it is speculated that suPAR is a low-grade inflammation marker reflecting on disease severity. The aim of this prospective observational study was to determine if the plasma concentration of suPAR is associated with admission time, re-admission, disease severity/Charlson Comorbidity Index Score, and mortality. METHODS: We included 543 patients with various diseases from a Danish Acute Medical Unit during a two month period. A triage unit ensured that only medical patients were admitted to the Acute Medical Unit. SuPAR was measured on plasma samples drawn upon admission. Patients were followed-up for three months after inclusion by their unique civil registry number and using Danish registries to determine admission times, readmissions, International Classification of Diseases, 10th Edition (ICD-10) diagnoses, and mortality. Statistical analysis was used to determine suPAR's association with these endpoints. RESULTS: Increased suPAR was significantly associated with 90-day mortality (4.87 ng/ml in survivors versus 7.29 ng/ml in non-survivors, P <0.0001), higher Charlson Score (P <0.0001), and longer admission time (P <0.0001), but not with readmissions. The association with mortality remained when adjusting for age, sex, C-reactive protein (CRP), and Charlson Score. Furthermore, among the various Charlson Score disease groups, suPAR was significantly higher in those with diabetes, cancer, cardiovascular disease, and liver disease compared to those without comorbidities. CONCLUSIONS: SuPAR is a marker of disease severity, admission time, and risk of mortality in a heterogeneous cohort of patients with a variety of diseases. The independent value of suPAR suggests it could be of value in prognostic algorithms.
Original languageEnglish
JournalCritical Care (Online Edition)
Volume16
Issue number4
Pages (from-to)R130
ISSN1466-609X
DOIs
Publication statusPublished - 2012

ID: 36301523